86.70
-2.34 (-2.63%)
| Penutupan Terdahulu | 89.04 |
| Buka | 89.60 |
| Jumlah Dagangan | 1,105,405 |
| Purata Dagangan (3B) | 740,154 |
| Modal Pasaran | 5,694,481,920 |
| Harga / Jualan (P/S) | 38.34 |
| Harga / Buku (P/B) | 84.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2025 |
| Margin Keuntungan | -123.28% |
| Margin Operasi (TTM) | -143.73% |
| EPS Cair (TTM) | -2.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 25.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 69.65% |
| Nisbah Semasa (MRQ) | 3.30 |
| Aliran Tunai Operasi (OCF TTM) | -113.49 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.71 M |
| Pulangan Atas Aset (ROA TTM) | -51.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -150.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Rhythm Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.65% |
| % Dimiliki oleh Institusi | 103.78% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 135.00 (JMP Securities, 55.71%) | Beli |
| Median | 107.00 (23.41%) | |
| Rendah | 95.00 (B of A Securities, 9.57%) | Beli |
| 95.00 (Needham, 9.57%) | Beli | |
| Purata | 110.00 (26.87%) | |
| Jumlah | 10 Beli | |
| Harga Purata @ Panggilan | 89.69 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Aug 2025 | 100.00 (15.34%) | Beli | 92.48 |
| Guggenheim | 06 Aug 2025 | 120.00 (38.41%) | Beli | 90.01 |
| JMP Securities | 06 Aug 2025 | 135.00 (55.71%) | Beli | 90.01 |
| 26 Jun 2025 | 84.00 (-3.11%) | Beli | 61.45 | |
| Morgan Stanley | 06 Aug 2025 | 109.00 (25.72%) | Beli | 90.01 |
| Canaccord Genuity | 18 Jul 2025 | 105.00 (21.11%) | Beli | 89.20 |
| B of A Securities | 10 Jul 2025 | 95.00 (9.57%) | Beli | 89.04 |
| Leerink Partners | 10 Jul 2025 | 102.00 (17.65%) | Beli | 89.04 |
| 07 Jul 2025 | 88.00 (1.50%) | Beli | 66.39 | |
| Oppenheimer | 10 Jul 2025 | 110.00 (26.87%) | Beli | 89.04 |
| Wells Fargo | 10 Jul 2025 | 129.00 (48.79%) | Beli | 89.04 |
| Needham | 09 Jul 2025 | 95.00 (9.57%) | Beli | 89.00 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |